Drug Profile
Research programme: spinal muscular atrophy therapeutics - Life Technologies Corporation/FSMA
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Families of SMA; Invitrogen Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Spinal muscular atrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Spinal-muscular-atrophy in USA
- 21 Dec 2005 Early research in Spinal muscular atrophy in USA (unspecified route)